- Conditions
- Advanced Solid Tumors
- Interventions
- DT-7012, Immune checkpoint inhibitor
- Drug
- Lead sponsor
- Domain Therapeutics Australia Pty Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 2,481
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Tourette Syndrome
- Interventions
- NBI-98854
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- San Diego, California • Kissimmee, Florida • St. Petersburg, Florida + 7 more
- Conditions
- Non-hodgkin Lymphoma
- Interventions
- Epcoritamab
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Miami, Florida • Valhalla, New York + 5 more
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil, Ramucirumab, Paclitaxel, Irinotecan, Capecitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Orange, California • Santa Monica, California • Chicago, Illinois + 8 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Delandistrogene Moxeparvovec, Standard of Care
- Genetic · Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 22 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- GS-0151, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 18
- States / cities
- Anniston, Alabama • La Jolla, California • Palo Alto, California + 15 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more
- Conditions
- Non Small Cell Lung Cancer (NSCLC)
- Interventions
- Bavituximab
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
- Conditions
- Ulcerative Colitis
- Interventions
- GB004, Placebo
- Drug
- Lead sponsor
- GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Monroe, Louisiana
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- CPI-1205, Cobicistat, Enzalutamide, Abiraterone, Prednisone
- Drug
- Lead sponsor
- Constellation Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 41
- States / cities
- Anchorage, Alaska • Beverly Hills, California • Duarte, California + 34 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- REOLYSIN®, Chemotherapy, Gemcitabine, Irinotecan, Leucovorin, 5-fluorouracil, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Solid Tumors
- Interventions
- BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 16
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Leukemia, Lymphocytic
- Interventions
- enzastaurin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • New York, New York + 1 more
- Conditions
- Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma
- Interventions
- NEO100
- Drug
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- GLB-001
- Drug
- Lead sponsor
- GluBio Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Duarte, California • Irvine, California • Kansas City, Kansas + 4 more
- Conditions
- Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Interventions
- PF-08634404, Ipilimumab
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 46
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 21 more
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer
- Interventions
- valemetostat tosylate, pembrolizumab
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 11
- States / cities
- La Jolla, California • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, EGFR Exon 20 Mutation, EGFR Exon 20 Insertion Mutation, EGFR Activating Mutation, Antineoplastic Agents, Metastatic Lung Cancer, Brain Metastases, EGFR-mutated NSCLC, EGFR Atypical Mutations, Including G719X and L861Q
- Interventions
- BLU-451, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Interventions
- Infigratinib, Tamoxifen, Omnipaque 350, Iopamidol, Computed tomography (CT)
- Drug · Diagnostic Test
- Lead sponsor
- Jennifer Lee Caswell-Jin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Healthy Volunteer
- Interventions
- BIIB142, BIIB142-Matching Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma
- Interventions
- KITE-197, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Miami, Florida • Chicago, Illinois • Nashville, Tennessee + 2 more
- Conditions
- Barrett Esophagus
- Interventions
- KSP/QRH dimer
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
- Interventions
- DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
- Other · Drug
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Augusta, Georgia • New York, New York + 3 more
- Conditions
- Post Menopausal, Hormone Receptor Positive Breast Cancer
- Interventions
- TAK700
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin